Eupraxia Pharmaceuticals Statistics
Total Valuation
EPRX has a market cap or net worth of $527.23 million. The enterprise value is $422.87 million.
| Market Cap | 527.23M |
| Enterprise Value | 422.87M |
Important Dates
The next estimated earnings date is Tuesday, November 3, 2026, after market close.
| Earnings Date | Nov 3, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
EPRX has 65.91 million shares outstanding. The number of shares has increased by 47.80% in one year.
| Current Share Class | 65.91M |
| Shares Outstanding | 65.91M |
| Shares Change (YoY) | +47.80% |
| Shares Change (QoQ) | +16.77% |
| Owned by Insiders (%) | 15.53% |
| Owned by Institutions (%) | 43.66% |
| Float | 55.67M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 4.07 |
| P/TBV Ratio | 5.18 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 16.00, with a Debt / Equity ratio of 0.01.
| Current Ratio | 16.00 |
| Quick Ratio | 15.71 |
| Debt / Equity | 0.01 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -66.70% and return on invested capital (ROIC) is -46.80%.
| Return on Equity (ROE) | -66.70% |
| Return on Assets (ROA) | -43.66% |
| Return on Invested Capital (ROIC) | -46.80% |
| Return on Capital Employed (ROCE) | -43.47% |
| Weighted Average Cost of Capital (WACC) | 12.39% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.08M |
| Employee Count | 49 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, EPRX has paid $55,002 in taxes.
| Income Tax | 55,002 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +43.29% in the last 52 weeks. The beta is 1.49, so EPRX's price volatility has been higher than the market average.
| Beta (5Y) | 1.49 |
| 52-Week Price Change | +43.29% |
| 50-Day Moving Average | 7.14 |
| 200-Day Moving Average | 7.28 |
| Relative Strength Index (RSI) | 53.88 |
| Average Volume (20 Days) | 592,505 |
Short Selling Information
The latest short interest is 7.11 million, so 10.79% of the outstanding shares have been sold short.
| Short Interest | 7.11M |
| Short Previous Month | 6.34M |
| Short % of Shares Out | 10.79% |
| Short % of Float | 12.78% |
| Short Ratio (days to cover) | 22.46 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -57.11M |
| Pretax Income | -50.18M |
| Net Income | -52.68M |
| EBITDA | -56.87M |
| EBIT | -57.11M |
| Earnings Per Share (EPS) | -$1.00 |
Balance Sheet
The company has $133.66 million in cash and $1.84 million in debt, with a net cash position of $131.82 million or $2.00 per share.
| Cash & Cash Equivalents | 133.66M |
| Total Debt | 1.84M |
| Net Cash | 131.82M |
| Net Cash Per Share | $2.00 |
| Equity (Book Value) | 129.67M |
| Book Value Per Share | 1.55 |
| Working Capital | 128.25M |
Cash Flow
In the last 12 months, operating cash flow was -$37.47 million and capital expenditures -$753,723, giving a free cash flow of -$38.23 million.
| Operating Cash Flow | -37.47M |
| Capital Expenditures | -753,723 |
| Depreciation & Amortization | 239,363 |
| Net Borrowing | n/a |
| Free Cash Flow | -38.23M |
| FCF Per Share | -$0.58 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
EPRX does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -47.80% |
| Shareholder Yield | n/a |
| Earnings Yield | -9.99% |
| FCF Yield | -7.25% |
Analyst Forecast
The average price target for EPRX is $16.35, which is 104.12% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $16.35 |
| Price Target Difference | 104.12% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 11 |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 2 |